Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
![]()
Spectra-Scope® will be simply a game changer for skin cancer diagnosis at an office setting
Share this Article:
Tweet
|
Company
Speclipse, Inc.
Headquarters
Silicon Valley, CA
Management
Sung Hyun Pyun, CEO
Description
Speclipse was founded by three Stanford University graduates and a dermatologist in November 2015, and currently has offices in Silicon Valley, California and South Korea. Diagnostic tools presently used by physicians such as dermascopes or confocal microscopes, provide 60-70% accuracy, far below that of Spectra-Scope®. Speclipse’s core diagnostic technology is available in two models. Spectra-Scope® is an “add-on module” which can be attached to existing aesthetic lasers at dermatology or primary care clinics to provide instant skin cancer diagnosis. The second diagnostic model offered is a “stand-alone” system which can be used without any additional equipment or accessories. It can be used by medical or cosmetic clinics who do not have existing laser equipment, or who prefer a small, portable stand-alone device for real-time diagnosis
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info